Poland
· Delayed Price · Currency is PLN Molecure Statistics
Total Valuation
Molecure has a market cap or net worth of PLN 190.25 million. The enterprise value is 167.23 million.
| Market Cap | 190.25M |
| Enterprise Value | 167.23M |
Important Dates
The last earnings date was Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Molecure has 16.84 million shares outstanding. The number of shares has increased by 4.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 16.84M |
| Shares Change (YoY) | +4.35% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 4.12% |
| Owned by Institutions (%) | 15.09% |
| Float | 10.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 125.02 |
| PB Ratio | 2.38 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.44 |
| EV / Sales | 109.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.97 |
Financial Position
The company has a current ratio of 8.81, with a Debt / Equity ratio of 0.07.
| Current Ratio | 8.81 |
| Quick Ratio | 8.49 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.17 |
| Interest Coverage | -581.69 |
Financial Efficiency
Return on equity (ROE) is -25.19% and return on invested capital (ROIC) is -15.67%.
| Return on Equity (ROE) | -25.19% |
| Return on Assets (ROA) | -15.15% |
| Return on Capital (ROIC) | -15.67% |
| Revenue Per Employee | 14,493 |
| Profits Per Employee | -292,892 |
| Employee Count | 111 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.30% in the last 52 weeks. The beta is 2.11, so Molecure's price volatility has been higher than the market average.
| Beta (5Y) | 2.11 |
| 52-Week Price Change | -38.30% |
| 50-Day Moving Average | 11.48 |
| 200-Day Moving Average | 14.80 |
| Relative Strength Index (RSI) | 60.16 |
| Average Volume (20 Days) | 33,649 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Molecure had revenue of PLN 1.52 million and -30.75 million in losses. Loss per share was -1.83.
| Revenue | 1.52M |
| Gross Profit | -1.72M |
| Operating Income | -31.90M |
| Pretax Income | -30.75M |
| Net Income | -30.75M |
| EBITDA | -30.11M |
| EBIT | -31.90M |
| Loss Per Share | -1.83 |
Balance Sheet
The company has 28.58 million in cash and 5.56 million in debt, giving a net cash position of 23.02 million or 1.37 per share.
| Cash & Cash Equivalents | 28.58M |
| Total Debt | 5.56M |
| Net Cash | 23.02M |
| Net Cash Per Share | 1.37 |
| Equity (Book Value) | 80.09M |
| Book Value Per Share | 4.76 |
| Working Capital | 26.78M |
Cash Flow
In the last 12 months, operating cash flow was -32.79 million and capital expenditures -838,881, giving a free cash flow of -33.63 million.
| Operating Cash Flow | -32.79M |
| Capital Expenditures | -838,881 |
| Free Cash Flow | -33.63M |
| FCF Per Share | -2.00 |
Margins
| Gross Margin | -112.84% |
| Operating Margin | -2,096.05% |
| Pretax Margin | -2,020.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -2,209.72% |
Dividends & Yields
Molecure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.35% |
| Shareholder Yield | -4.35% |
| Earnings Yield | -16.19% |
| FCF Yield | -17.68% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Molecure has an Altman Z-Score of 20.24.
| Altman Z-Score | 20.24 |
| Piotroski F-Score | n/a |